Evaluation of Myocardial Viability With Cardiac Magnetic Resonance Imaging

Suchi Grover, Govindarajan Srinivasan, Joseph B. Selvanayagam

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Assessment of myocardial viability is of clinical and scientific significance. Traditionally, the detection of myocardial viability (either stunning or hibernation) has been used in aiding diagnosis before revascularization, especially in high-risk patients. There is a considerable body of observational evidence showing substantial improvement after revascularization in patients with significant left ventricular dysfunction and myocardial viability. Recent randomized evidence has questioned the benefit of viability testing but must be interpreted with caution. Dobutamine stress echocardiography, nuclear imaging, and cardiovascular magnetic resonance are the mainstays of viability testing and provide information on contractile function, cellular metabolism, and myocardial fibrosis, respectively. Larger, multicenter trials with outcome data are needed to define the nature of viability testing and, particularly, cardiovascular magnetic resonance in moderate-to-severe ischemic cardiomyopathy.

LanguageEnglish
Pages204-214
Number of pages11
JournalProgress in Cardiovascular Diseases
Volume54
Issue number3
DOIs
Publication statusPublished - 1 Nov 2011

Keywords

  • Cardiovascular magnetic resonance
  • Late gadolinium enhancement
  • Left ventricular dysfunction
  • Myocardial viability
  • Revascularization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{3c2168018b1a4454aedfe33084ff6720,
title = "Evaluation of Myocardial Viability With Cardiac Magnetic Resonance Imaging",
abstract = "Assessment of myocardial viability is of clinical and scientific significance. Traditionally, the detection of myocardial viability (either stunning or hibernation) has been used in aiding diagnosis before revascularization, especially in high-risk patients. There is a considerable body of observational evidence showing substantial improvement after revascularization in patients with significant left ventricular dysfunction and myocardial viability. Recent randomized evidence has questioned the benefit of viability testing but must be interpreted with caution. Dobutamine stress echocardiography, nuclear imaging, and cardiovascular magnetic resonance are the mainstays of viability testing and provide information on contractile function, cellular metabolism, and myocardial fibrosis, respectively. Larger, multicenter trials with outcome data are needed to define the nature of viability testing and, particularly, cardiovascular magnetic resonance in moderate-to-severe ischemic cardiomyopathy.",
keywords = "Cardiovascular magnetic resonance, Late gadolinium enhancement, Left ventricular dysfunction, Myocardial viability, Revascularization",
author = "Suchi Grover and Govindarajan Srinivasan and Selvanayagam, {Joseph B.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1016/j.pcad.2011.06.004",
language = "English",
volume = "54",
pages = "204--214",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "3",

}

Evaluation of Myocardial Viability With Cardiac Magnetic Resonance Imaging. / Grover, Suchi; Srinivasan, Govindarajan; Selvanayagam, Joseph B.

In: Progress in Cardiovascular Diseases, Vol. 54, No. 3, 01.11.2011, p. 204-214.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of Myocardial Viability With Cardiac Magnetic Resonance Imaging

AU - Grover, Suchi

AU - Srinivasan, Govindarajan

AU - Selvanayagam, Joseph B.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Assessment of myocardial viability is of clinical and scientific significance. Traditionally, the detection of myocardial viability (either stunning or hibernation) has been used in aiding diagnosis before revascularization, especially in high-risk patients. There is a considerable body of observational evidence showing substantial improvement after revascularization in patients with significant left ventricular dysfunction and myocardial viability. Recent randomized evidence has questioned the benefit of viability testing but must be interpreted with caution. Dobutamine stress echocardiography, nuclear imaging, and cardiovascular magnetic resonance are the mainstays of viability testing and provide information on contractile function, cellular metabolism, and myocardial fibrosis, respectively. Larger, multicenter trials with outcome data are needed to define the nature of viability testing and, particularly, cardiovascular magnetic resonance in moderate-to-severe ischemic cardiomyopathy.

AB - Assessment of myocardial viability is of clinical and scientific significance. Traditionally, the detection of myocardial viability (either stunning or hibernation) has been used in aiding diagnosis before revascularization, especially in high-risk patients. There is a considerable body of observational evidence showing substantial improvement after revascularization in patients with significant left ventricular dysfunction and myocardial viability. Recent randomized evidence has questioned the benefit of viability testing but must be interpreted with caution. Dobutamine stress echocardiography, nuclear imaging, and cardiovascular magnetic resonance are the mainstays of viability testing and provide information on contractile function, cellular metabolism, and myocardial fibrosis, respectively. Larger, multicenter trials with outcome data are needed to define the nature of viability testing and, particularly, cardiovascular magnetic resonance in moderate-to-severe ischemic cardiomyopathy.

KW - Cardiovascular magnetic resonance

KW - Late gadolinium enhancement

KW - Left ventricular dysfunction

KW - Myocardial viability

KW - Revascularization

UR - http://www.scopus.com/inward/record.url?scp=80054778531&partnerID=8YFLogxK

U2 - 10.1016/j.pcad.2011.06.004

DO - 10.1016/j.pcad.2011.06.004

M3 - Article

VL - 54

SP - 204

EP - 214

JO - Progress in Cardiovascular Diseases

T2 - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 3

ER -